Adverse effects of GLP – 1 Receptor Agonists
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nau...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/57774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction and purpose
Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nausea, vomiting, diarrhoea, constipation and, less commonly, pancreatitis and cholelithiasis. In addition, a recent retrospective cohort study suggested a possible association between nonarteritic anterior ischaemic optic neuropathy (NAION) and the use of one of the GLP – 1 RAs, semaglutide. The aim of this article is to review the side effects associated with GLP – 1 RAs therapy.
|
|---|---|
| ISSN: | 2391-8306 |